Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

08/14/2026, 10:30 AM • The Motley Fool

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?

Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) offer different approaches to healthcare investing. FHLC provides broad diversification across 338 healthcare holdings with a lower 0.08% expense ratio, while IHE focuses on 56 pharmaceutical stocks with higher concentration risk but delivered 60% one-year returns. The analysis recommends FHLC for its superior diversification and lower costs, despite IHE's recent outperformance.

08/14/2026, 7:15 AM • The Motley Fool

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?

Simplify Health Care ETF (PINK) has delivered superior 1-year returns of 42% versus iShares U.S. Healthcare ETF's (IYH) 31.4%, driven by active management focused on healthcare innovation and a charitable mission donating profits to cancer research. However, IYH offers lower costs (0.38% vs 0.51% expense ratio), higher dividend yield (1.1% vs 0.6%), and a proven 25+ year track record, making it the more suitable choice for most long-term conservative investors despite PINK's recent outperformance.

08/13/2026, 3:34 PM • The Motley Fool

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly and Viking Therapeutics are competing in the rapidly growing GLP-1 drug market. Eli Lilly leads with approved products like tirzepatide generating strong revenue ($9.9B for Mounjaro, $4.9B for Zepbound in Q2), while Viking Therapeutics is a clinical-stage biotech with promising VK2735 candidate showing strong phase 2 results. The article recommends Eli Lilly as the safer choice due to its established portfolio and limited downside risk, though Viking Therapeutics offers higher upside potential if its phase 3 trials succeed.

08/08/2026, 3:30 PM • The Motley Fool

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) and State Street SPDR S&P Biotech ETF (XBI). XBI delivered superior 1-year returns of 80.2% with small-cap biotech focus but carries higher volatility (54% max drawdown). IXJ offers more stability with lower volatility, higher dividend yield (1.4%), and international diversification across large-cap pharmaceutical and healthcare companies. The analysis recommends XBI for long-term investors prioritizing performance despite greater risk.

08/08/2026, 12:02 PM • The Motley Fool

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

The article compares two healthcare sector ETFs: Vanguard Health Care ETF (VHT) with 423 holdings and State Street Health Care Select Sector SPDR ETF (XLV) with 60 holdings. While XLV has slightly lower expenses (0.08% vs 0.09%) and better 5-year returns, VHT outperforms on 1-year returns and offers broader diversification. The analysis recommends VHT for long-term investors due to superior recent performance and lower concentration risk.

08/08/2026, 11:33 AM • The Motley Fool

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly announced it will file for FDA approval of retatrutide, its next-generation weight-loss drug, in Q1 2027. The drug demonstrated 28.3% average weight loss over 80 weeks in phase 3 trials, outperforming competitors like Novo Nordisk's Wegovy. With strong Q2 financial results (48% revenue growth) and potential applications beyond obesity, Eli Lilly is positioned to expand its market lead.

08/07/2026, 6:30 PM • The Motley Fool

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

08/07/2026, 3:28 PM • The Motley Fool

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

Nxera Pharma reported strong Q2 2026 results with revenue of JPY 18.9 billion, up from the prior year, driven by eight R&D milestone events. The company achieved key regulatory designations for vamorolone in South Korea, progressed partnered programs with Neurocrine, Lilly, and AbbVie, and benefited from Lilly's acquisition of Centessa Pharmaceuticals. Operating profit turned positive at JPY 1.9 billion versus a prior loss, with core operating profit reaching JPY 6.5 billion.

08/07/2026, 2:30 AM • GlobeNewswire

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Viking Therapeutics stock fell 18.6% in July as investors focused on the company's cash burn ($96M quarterly) and potential shareholder dilution from a planned $500M equity offering, despite positive progress on its phase 3 trials for weight-loss drug VK2735. The company has sufficient cash through 2028 and expects trial results by then, maintaining long-term potential in the weight-loss drug market.

08/06/2026, 10:21 AM • The Motley Fool

Why Eli Lilly Stock Climbed Today

Eli Lilly's stock rose 4.86% following strong second-quarter earnings driven by surging sales of its obesity drugs Mounjaro and Zepbound, which grew 91% and 44% respectively. The company reported Q2 revenue of $23 billion (up 48% YoY) and adjusted net income of $7.5 billion, exceeding Wall Street expectations. Management raised its full-year revenue guidance to $85-87 billion and is investing profits into pipeline development through strategic acquisitions.

08/05/2026, 6:33 PM • The Motley Fool

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.

08/05/2026, 4:50 PM • GlobeNewswire

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk, making XLV the better choice for long-term investors seeking defensive characteristics.

08/05/2026, 3:02 PM • The Motley Fool

Is Eli Lilly Stock Running out of Steam?

Eli Lilly has surged over 300% in five years driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which generated 56% revenue growth in Q1. While the stock trades at a premium 40x earnings valuation, analysts argue it remains justified given upcoming pipeline catalysts like retatrutide (projected $3.8B revenue by 2030) and potential new indications for GLP-1 drugs. The stock is down 11% from highs, presenting a potential entry point for long-term investors.

08/03/2026, 1:29 PM • The Motley Fool

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool